Chugai Group’s mission is to create innovative drugs for the benefit of patients.

Message from the CEO

Hideaki Shimada PH.D.

Director, Chief Executive Officer

In the global medical field, there are many diseases for which there are no drugs, or where current drugs are insufficient to address the medical needs of patients. Chugai Pharmabody Research (CPR) is a subsidiary company of Chugai Pharmaceutical, a member of Roche group, and is committed to address these unmet needs.

CPR work on innovative drug discovery based on our proprietary global top level antibody engineering and cyclic peptide technology, and these novel technologies enables us to expand druggable target and invent unique modes of action to solve unmet medical needs. We also work on establishing novel antibody engineering and cyclic peptide technologies to continuously address unmet medical needs, and achieve competitive advantages in highly intense drug discovery field.

By taking full advantage of Singapore’s innovative environment for world-class biomedical research, cutting-edge infrastructure, highly trained and multi-national scientists and government support, we have established highly sophisticated antibody and cyclic peptide drug discovery platforms, and we are now global leader in the field of both antibody drug discovery and cyclic peptide drug discovery research.

CPR works as a unified team, and we are committed to making the best use of our R&D investments, resources and talents. Taken together, our aspirations are to discover innovative solutions for unmet medical needs, and to translate advanced science and technologies into revolutionary new antibody drugs that can significantly improve patients’ lives and contribute to the medical community around the world.


We aim to create innovative drug against the disease with high unmet medical needs for the human health around the world.

We will become a top innovator to realise advanced and sustainable patient-centric healthcare by our unique strength in science and technology with our highly diverse group of people having inclusive mind-set.


We create antibody drug clinical candidates using our proprietary antibody engineering technology platforms, and support drug development towards clinical development.

We identify biologically active cyclic peptide binders using our proprietary display technology platforms.

We develop innovative engineering technologies of proteins and cyclic peptides to create drugs even for difficult target molecules.


Patient Centric
Make each patient’s well-being our highest priority.

Pioneering Spirit
Pursue innovation by improving ourselves and thinking differently.

Maintain the highest standards in all we do to create shared value with society.

Company Profile

Chugai Pharmabody Research (CPR) was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd. (“Chugai”), Japan’ s No.1 biopharmaceutical company, and a member of Roche group, in January 2012 and started operations on July 2, 2012.

CPR conducts drug discovery research creating new antibody drug clinical candidates focusing on high value First-in-Class and Best-in-Class antibodies for a variety of targets and diseases using our proprietary antibody engineering technologies. CPR also conducts research utilizing our cyclic peptide drug discovery platform.

Company Name

Chugai Pharmabody Research Pte. Ltd.
(“Pharmabody” is coined from the words pharmaceutical and antibody.)


January 10, 2012


3 Biopolis Drive, #07–11 to 16 Synapse, Singapore 138623

Commencement of Operations

July 2, 2012


S$ 1.5 million


Hideaki Shimada Ph.D.


Wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd.

Board of Directors

Sir David Lane, Chairman of the Board

Hideaki Shimada, Director and CEO
Hisafumi Okabe, Director and COO
Arnold Levine, Director

Number of Employees

132 (as at 31 January 2021)




Juzo Ueno founded Chugai Shinkyaku Co., Ltd. and began the import and sale of medicinal drugs.



Reorganized into a corporation and company name changed to Chugai Pharmaceutical Co., Ltd. (Photo of Matsunage Plant)



Announcement of the strategic alliance with Roche and started business with Roche.



Established Chugai Pharmabody Research Pte. Ltd. In Singapore



Announcement of Business Expansion of Chugai Pharmabody Research Pte. Ltd.

Sir David Lane

Chairman of the Board and Chief Scientist at A*Star

With its proprietary antibody and cyclic peptide research technologies, CPR has great potential to create a world-leading technology platform that transforms the efficacy of antibody and cyclic based drugs and to contribute to a community of innovation. Since its establishment, through the research performance and other external activities such as organisation of antibody symposium, I realize that CPR’s presence in Singapore and expectation from others have been increasing. I am very proud to help CPR generate a pipeline of innovative products that will help patients around the world and interact very well with Singapore international research community.